NCT00138125 - Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

September 30, 2009

Study Completion Date

December 31, 2009

Conditions

Breast Cancer

Interventions

DRUG

Faslodex

Administered IM at 500 mg on day 1 of cycle 1, followed by 500 mg on day 15 of cycle 1, then 500 mg on day 1 of each cycle thereafter.

BIOLOGICAL

Herceptin

Given at 4 mg/kg IV on day 1 (cycle 1) then 2mg/kg IV weekly

Trial Locations (3)

Cancer Care Associates Medical Group, Inc, Redondo Beach

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles

San Antonio